CTCFL and cancer: NY-SAR-35 antigen, previously unexplored in bioinformatics, shares characteristics with BORIS, TMEM31, ACRBP, and SYCP1 in terms of its high expression on the cancer cells, notable immunogenicity, and absence of expression on the normal cells.